Dr. Tawbi on Evolving Treatment for Melanoma

Hussein A. Tawbi, MD, PhD
Published: Monday, Dec 03, 2018



Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment paradigm of melanoma.

For patients with resectable melanoma who start with skin primaries and develop nodal disease, surgery is very effective and sometimes curative. But there is still a high risk of relapse and mortality from melanoma, Tawbi says. In the last year alone, there have been a number of positive studies that have moved the needle for these patients who are at high risk of recurrence.

The anti-PD–1 agent nivolumab (Opdivo) was proven to be less toxic and more effective in terms of reducing the risk of relapse than the previous standard-of-care ipilimumab (Yervoy). An overall survival benefit was also seen, Tawbi adds.

For patients with BRAF-mutated melanoma, targeted agents are also making headway. Findings from a recent long-term study showed that the efficacy of dabrafenib (Tafinar) and trametinib (Mekinist) in these patients. The next step in this population would be combination strategies, Tawbi concludes.
SELECTED
LANGUAGE


Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment paradigm of melanoma.

For patients with resectable melanoma who start with skin primaries and develop nodal disease, surgery is very effective and sometimes curative. But there is still a high risk of relapse and mortality from melanoma, Tawbi says. In the last year alone, there have been a number of positive studies that have moved the needle for these patients who are at high risk of recurrence.

The anti-PD–1 agent nivolumab (Opdivo) was proven to be less toxic and more effective in terms of reducing the risk of relapse than the previous standard-of-care ipilimumab (Yervoy). An overall survival benefit was also seen, Tawbi adds.

For patients with BRAF-mutated melanoma, targeted agents are also making headway. Findings from a recent long-term study showed that the efficacy of dabrafenib (Tafinar) and trametinib (Mekinist) in these patients. The next step in this population would be combination strategies, Tawbi concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x